HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia.

Abstract
Antibiotic-resistant infections remain to be a major issue for all over the world. Although appropriate diagnosis and rapid treatment initiation are crucially important particularly in immunocompromised patients, selection of antibiotics without identification of causative bacteria is often challenging. A 44-year-old woman with acute myeloid leukemia (AML) under myelosuppression suffered from teicoplanin-resistant gram-positive cocci bacteremia. Taking severe neutropenia due to chemotherapy and glycopeptide-resistance into account, teicoplanin was empirically substituted with daptomycin, which led to prompt defervescence. This microorganism later turned out to be Leuconostoc lactis (L. Lactis), and daptmycin was continued to use based on antimicrobial susceptibility tests. As a result, empiric use of daptomycin successfully controlled glycopeptide-resistant gram-positive cocci bacteremia under neutropenia. This is the first report of daptomycin treatment for L. lactis bacteremia in a patient with AML under neutropenia. Our findings suggest that daptomycin would be a suitable treatment option for glycopeptide-resistant gram-positive cocci bloodstream infections, especially in myelosuppressive patients.
AuthorsKensuke Matsuda, Junji Koya, Kazuhiro Toyama, Mahoko Ikeda, Shunya Arai, Fumihiko Nakamura, Shu Okugawa, Kyoji Moriya, Mineo Kurokawa
JournalJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (J Infect Chemother) Vol. 23 Issue 11 Pg. 788-790 (Nov 2017) ISSN: 1437-7780 [Electronic] Netherlands
PMID28743428 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2017. Published by Elsevier Ltd.
Chemical References
  • Anti-Bacterial Agents
  • Immunosuppressive Agents
  • Teicoplanin
  • Vancomycin
  • Daptomycin
Topics
  • Adult
  • Anti-Bacterial Agents (pharmacology, therapeutic use)
  • Bacteremia (blood, drug therapy, microbiology)
  • Chemotherapy-Induced Febrile Neutropenia (blood, drug therapy, microbiology)
  • Daptomycin (pharmacology, therapeutic use)
  • Drug Resistance, Bacterial
  • Enterococcus (drug effects, isolation & purification, pathogenicity, physiology)
  • Female
  • Gram-Positive Bacterial Infections (blood, drug therapy, microbiology)
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents (adverse effects)
  • Leuconostoc (drug effects, isolation & purification, pathogenicity, physiology)
  • Leukemia, Myeloid, Acute (drug therapy)
  • Microbial Sensitivity Tests
  • Teicoplanin (pharmacology, therapeutic use)
  • Vancomycin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: